Background and objective
========================

The B-cell population comprises B1 and B2; the B1 population is subdivided into B1a, which express CD5, and B1b, which do not. B1 cells contribute to autoimmune disease, and a negative regulation has been ascribed to CD5. We recently described an alternative exon1 (referred as exon1B) and pursued the issue of the interplay of two exons 1 in the pathogenesis of lupus.

Methods
=======

B cells, including the B1a, B1b and B2 subpopulations, and T cells, were sorted from periperal blood (PB), tonsils, cord blood (CB) and CLL samples. Jurkat and Daudi cells were used as positive and negative controls, respectively. Conventional, nested and real-time PCR, *in situ* hybridization and EBV transformation were used, and CD5 molecules were counted.

Results
=======

Exon 1B was shown to encode an additional mRNA in B cells and to be functional. It was never found in T cells, including those activated by anti-CD3 plus IL-2 or PMA. There was a gradient expression of exon 1A: PB T cells \> B CLL \> tonsil B (B1a \> B1b \> B2), \> PB B \> CB B cells. This correlated with the CD5 molecule at the membrane. *In situ* hybridization of cytospan cells and germinal center sections confirmed this statement. Exon 1A substituted to exon 1B in activated (anti-μ plus IL-2), but not in further advanced (anti-μ plus IL-4) B cells. The leader peptide of exon-1B-induced protein was hydrophilic (not expressed) while that of exon-1A-induced protein was hydrophobic (expressed).

Conclusion
==========

An aberrant exon 1B usage prevents transportation of CD5 to the membrane. Given the negative control exerted by CD5 in the vicinity of the BCR, B-cell-mediated autoimmune disease might thus occur as a failure to express CD5.
